Nocutil Melt (Desmopressin Acetate)

Desmopressin Acetate, the active ingredient in Nocutil Melt, is a vasopressin analog presented as a sublingual melt for sublingual use. It is employed to manage central diabetes insipidus, nocturnal enuresis, and certain bleeding disorders such as hemophilia A and von Willebrand disease.\n\nGNH India supplies Nocutil Melt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desmopressin acetate is indicated for disorders that involve antidiuretic deficiency or impaired hemostasis.\n\nCentral diabetes insipidus: reduces excessive urine output and stabilises fluid balance.\nNocturnal enuresis: decreases the frequency of nighttime bedwetting episodes.\nHemophilia A: raises plasma factor VIII levels to improve clotting function.\nVon Willebrand disease: increases von Willebrand factor concentrations to support normal haemostasis.

Desmopressin acetate may cause a range of adverse reactions, from mild to serious.\n\nCommon Side Effects:\n- Headache: mild to moderate intensity.\n- Nausea: occasional, often transient.\n- Facial flushing: transient redness of the skin.\n- Nasal congestion: mild blockage of nasal passages.\n- Mild hyponatraemia: slight reduction in serum sodium.\n\nSerious or Rare Side Effects:\n- Severe hyponatraemia: can lead to cerebral oedema and seizures.\n- Seizures: associated with profound electrolyte disturbance.\n- Water intoxication: excessive fluid retention causing confusion or coma.\n- Allergic reactions: including rash, angioedema or anaphylaxis.\n- Thromboembolic events: rare clot formation in veins or arteries.

Before prescribing Nocutil Melt, clinicians should consider several safety measures.\n\nAssess serum sodium: verify baseline electrolytes to detect existing hyponatraemia.\nMonitor fluid intake: advise patients to limit excessive water consumption.\nAvoid concomitant antidiuretic agents: concurrent use with other ADH analogues can amplify water retention.\nUse caution in renal impairment: reduced clearance may increase drug exposure.\nAdjust dose in elderly: age‑related pharmacokinetic changes may require lower dosing.\nStore at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Desmopressin acetate can interact with several medicines, altering its safety profile.\n\nMajor Interactions (Avoid):\n- Carbamazepine: induces hepatic metabolism, reducing desmopressin efficacy.\n- NSAIDs: increase risk of hyponatraemia by enhancing renal water reabsorption.\n- Thiazide diuretics: potentiate water retention and hyponatraemia.\n\nModerate Interactions (Monitor Closely):\n- SSRIs (selective serotonin reuptake inhibitors): may predispose to hyponatraemia.\n- ACE inhibitors: can augment antidiuretic effects and fluid overload.\n- Warfarin: altered haemostatic response may require closer coagulation monitoring.